广告
加载中

携类风湿、强直性脊柱炎多适应症管线 凌科药业二次冲刺港交所

孟祥娜 2026-07-15 13:46
孟祥娜 2026/07/15 13:46

邦小白快读

EN
全文速览

本文主要介绍了国内创新药企凌科药业二次递表港交所冲刺上市的全过程,梳理了行业背景、企业情况与面临的挑战,核心重点干货如下:

1. 行业背景:国内自身免疫性疾病治疗药物市场高速增长,市场规模从2019年的162亿元增长到2024年328亿元,机构预测2026年将突破540亿元,以JAK抑制剂为代表的口服小分子靶向药是当前赛道主流方向。

2. 企业核心情况:凌科药业2017年由海归研发团队创立,核心管线覆盖类风湿关节炎等自免疾病以及中枢神经退行性疾病,目前暂无产品商业化,2024-2025年累计亏损5亿元,主要依靠管线对外授权获得资金,目前已经完成核心自免产品的三期临床。

3. 面临的挑战:早期零对价股权转让引发监管问询,创始人股权占比低无控股股东,赛道竞争激烈,自身缺乏商业化团队,突围难度较大。

本文梳理了国内自身免疫疾病药物赛道的发展趋势与竞争格局,能给同赛道医药品牌商提供多维度参考,核心干货如下:

1. 行业与消费趋势:国内自免药物市场正高速扩容,该品类是全球仅次于肿瘤的第二大药物市场,患者基数大用药周期长,口服小分子靶向药替代注射生物制剂、高选择性第二代JAK抑制剂替代第一代低选择性产品是明确的发展趋势,市场空间广阔。

2. 产品研发方向:后发品牌可以走差异化突围路线,可选择挖掘白癜风、斑秃等空白适应症,也可通过优化药物安全性打造优势,还可尝试跨领域布局自免炎症+中枢神经疾病管线,避开同质化竞争。

3. 竞争与合作启示:当前头部药企已经凭借医保、成本优势完成卡位,缺乏商业化能力的新兴品牌可以和成熟药企合作,通过出让销售权换取成熟的销售渠道与临床支持,缓解自身资金与能力短板。

本文梳理了国内创新自免药物赛道的最新变化,能给药品领域从业者提供机会与风险参考,核心干货如下:

1. 市场机会:自免药物市场规模持续高速增长,第二代高选择性JAK抑制剂凭借安全性优势获得临床青睐,拥有独家适应症、安全优势的产品仍有抢占市场的机会,中枢神经方向的TYK2靶点药物也有广阔的探索空间。

2. 风险提示:当前JAK抑制剂赛道已经趋于拥挤,仅类风湿关节炎适应症就有15款产品获批,十余个产品在研,头部恒瑞等企业已经凭借本土化销售网络和医保优势抢占市场,后发产品突围难度非常大。

3. 可借鉴的模式:没有商业化团队的创新药企可以采用和成熟企业合作的模式,由合作方提供临床服务和独家销售权,通过里程碑付费、预付款的方式合作,既补齐自身短板也分摊了风险,该模式具备可复制性。

4. 合规提示:创新药企境外上市需要关注股权变更的合规性,早期股权交易定价需要明确逻辑,无偿转让等定价差异容易引发监管问询,需要提前做好合规梳理。

本文梳理了国内创新药赛道的研发热点与需求,给医药生产相关工厂的干货内容如下:

1. 生产与产品需求变化:当前国内自免药物赛道的研发热点集中在第二代高选择性JAK1抑制剂、外用JAK抑制剂、TYK2靶点中枢神经疾病药物,随着管线逐步推进到上市阶段,对应品类的原料药、制剂生产需求会持续增长,相关生产工厂可以提前布局对应产能。

2. 商业合作机会:当前新兴创新药企普遍侧重研发环节,多数没有完备的自主生产产能,更倾向于外包生产或者合作生产,像凌科药业这类创新药企虽然自身负责核心产品供货,但后续产品上市放量后,会释放大量的代工生产需求,工厂可以主动对接这类临床阶段创新药企寻求长期合作。

3. 转型启示:创新药管线更新迭代快,对生产的灵活性要求更高,工厂需要提升柔性生产能力,匹配创新药企小批量多批次的研发生产需求,才能抓住新兴赛道的合作机会。

本文梳理了当前国内临床阶段创新药企的核心痛点与行业需求,给医药领域服务商的干货内容如下:

1. 行业发展趋势:国内创新药行业快速发展,大量创新药企处于临床研发阶段,对第三方研发、合规、商业化服务的需求持续增长,赛道整体市场空间不断扩大。

2. 客户核心痛点:临床阶段创新药企普遍面临三大痛点,一是资金压力大,未商业化前没有稳定营收,需要通过对外合作获取资金;二是缺乏商业化能力,没有成熟的销售团队和市场准入经验;三是早期股权架构设计不规范,境外上市面临合规核查压力。

3. 业务拓展方向:服务商可以拓展全链条服务,针对创新药企需求推出覆盖临床研发、合规梳理、商业化合作的一体化服务,类似先声药业为凌科药业提供CRO加独家销售权的合作模式,既可以获得预付款和里程碑收入,也能和创新药企绑定实现长期收益,挖掘新的增长空间。

本文展现了创新药企赴境外上市的相关情况与核心问题,给相关平台的干货内容如下:

1. 市场需求:当前国内大量临床阶段创新药企有强烈的上市融资需求,需要通过上市融资获得管线研发与商业化的资金,港交所等境外平台是国内创新药企上市的热门选择,创新药赛道仍然有丰富的优质项目储备。

2. 平台需要关注的风险与审核要点:创新药企早期发展过程中,经常会出现零对价无偿股权转让等股权安排,容易出现内外定价差异大的问题,引发定价公允性质疑,平台审核需要重点核查股权变更的定价逻辑与合规性。此外,多轮融资后创新药企容易出现创始人持股比例低、无控股股东的情况,股权高度分散会带来治理风险,也需要重点问询核查,做好股东穿透工作。

3. 招商方向:自免药物赛道增长潜力大,管线清晰的临床阶段创新药企是优质的上市项目来源,平台可以针对性挖掘对接这类项目,丰富自身的项目储备。

本文对国内JAK抑制剂创新药赛道的最新发展做了完整梳理,给产业研究者的核心干货如下:

1. 产业新动向:国内自身免疫药物市场进入高速增长期,JAK抑制剂赛道已经完成升级迭代,第二代高选择性产品成为主流,后发企业普遍采用差异化竞争策略,除了挖掘空白适应症外,不少企业开始跨领域布局自免炎症+中枢神经退行性疾病管线,管线对外授权已经成为临床阶段创新药企获得研发资金的重要商业模式。

2. 产业新问题:当前后发创新药企面临多重困境,首先是头部企业已经完成先发卡位,赛道同质化竞争严重,存量竞争压力大;其次是多数创新药企缺乏商业化能力,没有成熟的销售体系和市场准入经验;此外,早期股权架构设计不规范容易引发合规风险,股权高度分散也会带来公司治理层面的不确定性。

3. 新商业模式研究方向:新兴创新药企和成熟本土药企合作,由成熟药企提供临床服务与商业化销售,创新药企保留研发生产权益,这种分工合作的轻资产商业化模式,为后发创新药企突围提供了新路径,值得深入研究其适用性与风险点。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article details the full process of Chinese innovative biopharma company LinkMed Therapeutics' second IPO filing to pursue a listing on the Hong Kong Stock Exchange. It outlines the industry background, company profile and key challenges the firm faces, with key takeaways as follows:

1. Industry background: China's autoimmune disease drug market is growing rapidly, expanding from RMB 16.2 billion in 2019 to RMB 32.8 billion in 2024, with industry forecasts projecting it will exceed RMB 54 billion by 2026. Oral small-molecule targeted drugs represented by JAK inhibitors are currently the mainstream development direction in the sector.

2. Company overview: Founded in 2017 by a returnee R&D team from overseas, LinkMed's core pipelines cover autoimmune diseases such as rheumatoid arthritis and central neurodegenerative diseases. The company has not yet commercialized any products, and posted cumulative losses of RMB 5 billion between 2024 and 2025. It primarily funds operations through out-licensing of its pipelines, and has completed Phase III clinical trials for its core autoimmune drug candidate.

3. Key challenges: Early zero-consideration equity transfers have triggered regulatory inquiries. Founders hold a low stake and the company has no controlling shareholder. The sector is highly competitive, and LinkMed lacks an in-house commercialization team, making market breakthrough very challenging.

This article outlines the development trends and competitive landscape of China's autoimmune disease drug sector, providing multi-dimensional insights for peer pharmaceutical brands. Key takeaways are as follows:

1. Industry and consumer trends: China's autoimmune drug market is expanding rapidly. The autoimmune drug category is the world's second-largest drug market after oncology, with a large patient base and long treatment cycles. Clear industry trends include oral small-molecule targeted drugs replacing injectable biologics, and second-generation high-selectivity JAK inhibitors replacing first-generation low-selectivity products, leaving enormous room for market growth.

2. Product R&D direction: Late-moving brands can pursue a differentiated breakthrough strategy by either targeting underserved indications such as vitiligo and alopecia areata, building competitive advantages through optimized drug safety profiles, or exploring cross-field pipelines combining autoimmune inflammation and central nervous system diseases to avoid homogenized competition.

3. Insights on competition and collaboration: Leading pharmaceutical companies have already secured strong market positions via national drug insurance access and cost advantages. Emerging brands lacking commercialization capabilities can partner with established pharma firms, trading sales rights in exchange for access to mature distribution channels and clinical support to offset their own funding and capability gaps.

This article summarizes the latest developments in China's innovative autoimmune drug sector, providing insights into opportunities and risks for pharmaceutical industry practitioners. Key takeaways are as follows:

1. Market opportunities: The autoimmune drug market continues to grow at a high pace. Second-generation high-selectivity JAK inhibitors have gained clinical traction thanks to their better safety profiles. Products with exclusive indications and safety advantages still have room to capture market share, and TYK2-targeted drugs for central nervous system indications also offer broad exploration space.

2. Risk warnings: The JAK inhibitor track is already crowded. As many as 15 products targeting rheumatoid arthritis alone have been approved, with more than 10 additional candidates in clinical development. Leading domestic players such as Hengrui have already captured large market shares through localized sales networks and national insurance access advantages, making it extremely difficult for late-moving products to break through.

3. Replicable partnership model: Innovative bioteams without an in-house commercialization team can partner with established pharmaceutical firms, where partners provide clinical services and exclusive sales rights under a structure of upfront payments plus milestone payments. This model addresses gaps in capabilities and shares risks, and is replicable across the industry.

4. Compliance reminder: Innovative biotechs seeking overseas listings must pay close attention to the compliance of equity changes. Early equity transactions require clear pricing logic, as unusual pricing such as free transfers can easily trigger regulatory inquiries, so compliance reviews should be conducted in advance.

This article outlines R&D hotspots and market demands in China's innovative drug sector, with key insights for pharmaceutical manufacturing facilities as follows:

1. Shifts in production and product demand: Current R&D hotspots in China's autoimmune drug sector focus on second-generation high-selectivity JAK1 inhibitors, topical JAK inhibitors, and TYK2-targeted drugs for central nervous system diseases. As these pipelines advance toward approval, demand for API and preparation manufacturing for the corresponding categories will continue to grow. Relevant manufacturing facilities can prepare by expanding capacity for these product types in advance.

2. Business collaboration opportunities: Most emerging innovative biotechs focus heavily on R&D and lack comprehensive in-house manufacturing capacity, so they prefer contract manufacturing or joint production arrangements. While LinkMed handles manufacturing of its lead product in-house, it will release massive contract manufacturing demand once its pipeline products launch and scale up. Facilities can proactively connect with clinical-stage innovative biotechs to pursue long-term collaboration opportunities.

3. Transformation insights: Innovative drug pipelines evolve rapidly and require higher production flexibility. Manufacturing facilities need to improve their flexible production capabilities to match the small-batch, multi-batch R&D and production demands of innovative biotechs, in order to capture collaboration opportunities in this emerging sector.

This article summarizes the core pain points and industry demands of current clinical-stage innovative biotechs in China, with key insights for pharmaceutical service providers as follows:

1. Industry development trends: China's innovative drug industry is growing rapidly, with a large number of innovative biotechs in the clinical development stage. Demand for third-party R&D, compliance and commercialization services continues to rise, driving continuous expansion of the overall market size.

2. Core customer pain points: Clinical-stage innovative biotechs generally face three key pain points: first, heavy funding pressure, with no stable revenue before commercialization, forcing them to raise funds through external partnerships; second, lack of commercialization capabilities, with no mature sales team or market access experience; third, non-standard early equity structure design, leading to compliance scrutiny pressure for overseas listings.

3. Business expansion direction: Service providers can develop end-to-end services, launching integrated solutions covering clinical R&D, compliance review, and commercialization partnerships to match innovative biotechs' needs. This mirrors the partnership model between Simcere and LinkMed, where Simcere provides CRO services and exclusive sales rights. This model allows service providers to earn upfront and milestone revenue, build long-term tied partnerships with innovative biotechs, and unlock new growth opportunities.

This article presents the background and core issues related to innovative biotechs pursuing overseas listings, with key insights for listing platforms as follows:

1. Market demand: Currently, a large number of clinical-stage innovative biotechs in China have strong demand for listing to raise funds for pipeline R&D and commercialization. Overseas platforms such as the Hong Kong Stock Exchange are popular listing destinations for Chinese innovative biotechs, and the innovative drug sector still has a rich pipeline of high-quality projects.

2. Key risks and review priorities for platforms: During the early development of innovative biotechs, equity arrangements such as zero-consideration free transfers are common, which can easily lead to large pricing gaps between internal and external transactions and trigger questions over pricing fairness. Platforms need to prioritize review of the pricing logic and compliance of equity changes. In addition, after multiple rounds of financing, innovative biotechs often have low founder shareholdings and no controlling shareholder; highly dispersed equity creates governance risks, so platforms also need to conduct targeted inquiries and due diligence, including full shareholder penetration.

3. Project sourcing direction: The autoimmune drug sector has strong growth potential, and clinical-stage innovative biotechs with clear pipelines are high-quality listing project sources. Platforms can proactively source and connect with this type of project to enrich their project pipeline.

This article provides a comprehensive overview of the latest developments in China's JAK inhibitor innovative drug sector, with key insights for industry researchers as follows:

1. New industry trends: China's autoimmune drug market has entered a period of high growth, and the JAK inhibitor sector has completed iterative upgrade, with second-generation high-selectivity products becoming the mainstream. Late-moving players generally adopt differentiated competition strategies: in addition to developing underserved indications, many companies are expanding into cross-field pipelines combining autoimmune inflammation and central neurodegenerative diseases. Pipeline out-licensing has become an important business model for clinical-stage innovative biotechs to raise R&D funding.

2. New industry challenges: Late-moving innovative biotechs face multiple headwinds. First, leading players have already secured first-mover positions, leaving the sector facing homogenized competition and intense存量 competition pressure. Second, most innovative biotechs lack commercialization capabilities, with no mature sales system or market access experience. In addition, non-standard early equity structure design can easily trigger compliance risks, and highly dispersed equity also creates uncertainty over corporate governance.

3. New research direction for business models: A new asset-light commercialization model has emerged, where emerging innovative biotechs partner with established domestic pharma firms: the established partner provides clinical services and commercial sales, while the innovative biotech retains R&D and manufacturing rights. This division-of-labor model provides a new path for late-moving innovative biotechs to break through, and its applicability and risk profile deserve further in-depth research.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

近年来,中国 自身免疫性疾病治疗药物市场正迎来高速扩容,规模由2019年162亿元攀升至2024年328亿元,机构预测2026年市场总量有望突破540亿元。

这片蓝海之中,以JAK抑制剂为代表的口服小分子靶向药物,凭借口服给药替代注射生物制剂的独特优势,持续改写国内自免疾病临床治疗格局。

赛道热度之下,临床阶段生物药企也迫切需要借助上市融资,来推进研发和管线商业化。近日,专注自身免疫及炎症疾病小分子抑制剂研发的凌科药业二度递表港交所。

然而,在恒瑞医药等国内巨头已率先实现JAK抑制剂商业化的竞争格局下,后来者凌科药业究竟手握哪些差异化筹码,又面临着怎样的现实短板?其管线布局能否在巨头环伺下撕开一道口子,抢占一席之地?

1

海归博士组团创业,无偿转让股权引监管问询

2017年,国内创新药改革迎来发展浪潮,大批具备跨国药企研发背景的华人科学家回国创业,曾任强生亚太核心研发高管、拥有二十余年新药研发经验的万昭奎正是其中一员。

彼时行业存在明显供需缺口,全球自身免疫疾病已进入精准靶向治疗阶段,但国内患者只能依赖副作用突出的传统药物,国产高安全、高品质JAK靶向药物市场近乎空白。

看准行业机遇,万昭奎2017年联合三位资深行业合伙人,在杭州创立凌科药业。

其团队成员各有所长,前默克首席科学家汪俊、辉瑞药物副研究员Michael Vazquez、产业资本运营专家陈龑共同组成联合创始人班子,覆盖药物研发、技术攻坚、资本运营全链条。

四人背景差异鲜明,万昭奎、汪俊、Michael Vazquez均为美籍博士,具备海外博士后研究履历;唯一中国籍创始人陈龑毕业于中国药科大学。

依托完整的研发管线,凌科药业完成多轮融资,累计募资3.6亿元,君联惠康、健妙、礼安凌杭、苏州礼润等机构均参与投资。伴随外部机构进场,创始团队也通过股权转让实现部分股权变现。

据「创业最前线」不完全统计,多笔市场化股权交易完成后,万昭奎累计获转让款3175万元,汪俊获得转让收益520万元,员工持股平台菱欣合伙企业出让股权合计回款305万元。

公司早期搭建内部股权架构时,曾开展多笔零对价无偿股权转让。

2018年6月,汪俊分别从万昭奎、境外持股平台Lynk Investment受让对应注册资本17.7万元、14.6万元股权,菱欣合伙企业同步无偿受让万昭奎所持215.5万元注册资本股权,全部交易无需受让方支付转让价款。其中,Lynk Investment由万昭奎、汪俊、Michael Vazquez分别持股26.14%、18.26%、55.6%。

后续,菱欣合伙企业又在2020年12月、2021年7月分两次参与公司增资,合计认购新增注册资本257.02万元,招股书并未披露价格;同期,外部机构健妙入股价格已达40元/股。

一方面是内部无偿受让,另一方面却是高达40元/股的入股价格,内外交易定价形成显著落差。巨大价差引发监管重点关注。

在凌科药业首次递交境外上市申请后,证监会于今年1月19日下发境外上市备案问询函,将历次股权变动定价逻辑、零对价股权转让的商业公允性列为核心核查要点,要求企业完整披露全套佐证材料,对相关交易合理性作出充分解释。

完成股权沿革合规梳理与整改后,凌科药业于2026年6月向港交所二次递交招股书重启上市进程,高度分散的股权结构也成为市场讨论焦点。

经过多轮机构融资,四位创始人合计仅掌握公司34.42%投票权,机构股东总持股比例过半,招股书亦未披露创始人之间存在一致行动协议。

针对这一股权特征,监管同步提出专项问询,要求公司充分论证无控股股东的认定依据,完成全部股东穿透核查,梳理存在关联、一致行动关系股东的实际控制人与合并持股比例,并明确股东人数的计算规则及法律依据。

2

对外授权成主要收入来源,市场化前景待验证

在监管机构关注股权沿革与治理合规之外,资本市场对凌科药业IPO价值的核心研判,更多聚焦于其自主研发管线的技术含金量、未满足临床需求的覆盖能力以及行业竞争格局中的差异化定位。

凌科药业当前虽尚未实现产品商业化,但其临床管线已形成清晰的双轮驱动战略——以口服选择性JAK1抑制剂LNK01001主攻全身性自身免疫疾病(如类风湿关节炎、强直性脊柱炎),以外用软性泛JAK抑制剂LNK01004深耕皮肤局部炎症领域(如特应性皮炎),两者协同覆盖骨关节与皮肤两大核心自免场景。

在此基础上,公司还以TYK2抑制剂LNK01006前瞻性切入中枢神经系统疾病赛道,布局帕金森病、阿尔茨海默病等神经退行性疾病,意在打造另一重点研发领域。

行业层面,国内同赛道企业高光制药,与凌科药业的管线布局具备较高相似度,二者均同步深耕外周自身免疫炎症与中枢神经退行性疾病两大核心领域,规避传统JAK药物的同质化竞争,是国内少数同时布局“自免炎症+中枢神经疾病”的创新药企。

不过,与凌科药业的单靶点策略不同,高光制药以双靶点为核心,TLL-018(TYK2/JAK1)主攻慢性自发性荨麻疹和类风湿关节炎等适应症,TLL-041(脑渗透性TYK2/JAK1)则专门用于神经退行性疾病的治疗。

从财务情况来看,凌科药业的核心产品均处于临床试验阶段,尚未实现药品商业化落地,缺乏稳定、可持续的经营性营收。

2024年及2025年,公司尚未产生主营业务收入,两年累计亏损5亿元。在此背景下,管线对外授权合作成为公司维持研发、运营开支的主要资金补充渠道之一。

2026年第一季度,公司获得了一笔3864.3万元管线对外授权合作首付款。

早在2025年12月,凌科药业与Bleecker Bio达成合作协议,根据合作协议,凌科药业将LNK01006除中国内地、中国香港、中国澳门及中国台湾地区之外的全球开发、生产与商业化权益,独家授予Bleecker Bio。

作为交易对价,Bleecker Bio将向凌科药业支付500万美元预付款,同时出具对应10%持股比例的股份认购权证,让凌科药业直接持有Bleecker Bio一成股权;凌科药业还拥有在达成特定临床开发、监管审批及商业化里程碑时收取额外款项的权利,里程碑付款总额最高可达6.05亿美元(折合人民币约40亿元以上)。

对外授权合作的模式在行业层面有迹可循。

2023年3月,高光制药与全球神经科学企业Biohaven达成TLL-041海外独家授权合作,授予对方大中华区外全部中枢神经系统(CNS)适应症研发、生产、商业化权益。其交易对价包含1000万美元预付款、721136股Biohaven股票、最高9.5亿美元里程碑付款及分级销售特许权。

对比来看,高光制药的授权交易在金额上比凌科药业更为优厚——预付款高出500万美元,里程碑上限高出3亿美元。

若将视线拉回行业常识,中枢神经系统靶向药物的开发历来以高失败率著称。首付款与里程碑数字固然吸睛,却无法绕过临床试验这道硬门槛。

无论凌科药业LNK01006的别构型TYK2设计,还是高光制药TLL-041的双靶点思路,目前均处于临床研发阶段,靶点选择性优势能否转化为临床获益,安全性能否支撑长期给药,都有待后续II期及更大样本试验给出答案。

3

头部竞品已上市卡位,后发管线突围难度陡增

除中枢神经系统靶向药物这张王牌外,凌科药业的核心自免药物管线亦蓄势待发,但同样面临激烈的市场竞争。

自身免疫性疾病(如类风湿关节炎、强直性脊柱炎、特应性皮炎等)患者基数庞大、用药周期长,是全球仅次于肿瘤的第二大药物市场。

大量自身免疫病的发病机制均依赖JAK介导的异常免疫信号传导,因此靶向阻断JAK通路的JAK抑制剂能够从源头抑制过度活化的免疫炎症,成为这类疾病核心治疗药物。

早期上市的第一代泛JAK抑制剂(如芦可替尼、托法替布、巴瑞替尼)选择性较低,通过广谱抑制实现疗效,在多个适应症上取得商业成功——2022年芦可替尼全球销售额达39.7亿美元,托法替布17.96亿美元,巴瑞替尼8.3亿美元。

但第一代药物因靶点覆盖过宽,临床应用中常伴随感染、血栓、血脂异常及恶性肿瘤等风险,部分品种带有FDA黑框警告,安全性问题在一定程度上限制了其长期使用和用药人群的拓展。

第二代JAK抑制剂则通过高选择性抑制特定亚型(如JAK1、JAK3、TYK2),在保留疗效的同时显著减少了脱靶相关副作用,安全性更优,成为临床更青睐的选择。代表药物乌帕替尼上市三年即突破25亿美元销售额,增速超越前代,验证了精准靶向的市场价值。

国内现已有多款二代高选择性JAK抑制剂落地,赛道竞争格局清晰。

除进口产品外,恒瑞医药硫酸艾玛昔替尼片2025年获批,一举拿下活动性强直性脊柱炎、类风湿关节炎、中重度特应性皮炎、重度斑秃四大适应症,填补国产JAK抑制剂斑秃治疗空白,依托成本与医保优势加速拓展市场。

眼下国内JAK抑制剂赛道竞争日趋激烈,各家药企突围思路明确:或是区分靶点形成差异化赛道,或是挖掘斑秃、白癜风等空白适应症,亦或是依托安全性优化、价格优势争夺患者资源。

未来,拥有独家适应症、机制安全优势的高选择性二代JAK抑制剂,或将持续占据市场核心地位。

凌科药业布局了两款差异化产品:LNK01001为口服高选择性JAK1抑制剂,也就是第二代JAK抑制剂,覆盖类风湿关节炎、强直性脊柱炎、特应性皮炎及白癜风;LNK01004为外用软性泛JAK抑制剂,针对轻中度特应性皮炎。

进度上,LNK01001已于2026年1月完成类风湿关节炎III期临床,针对特应性皮炎适应症已提交上市申请,预计2026年下半年及2027年下半年分别申报类风湿关节炎和强直性脊柱炎适应症。

另一管线LNK01004于2025年7月完成II期临床试验,计划2027年上半年启动III期。

然而,从部分适应症来看,国内二代JAK1抑制剂赛道已趋于拥挤。

以类风湿关节炎适应症为例,国内已有15项靶向药物获批(7项小分子+8项生物制剂),另有11项JAK抑制剂处于I期、2项处于II期,高光制药、凌科药业、无锡福欣的产品处于III期,后发者面临激烈存量竞争。

凌科药业迄今无上市产品,商业化团队空白,缺乏销售、医学事务和市场准入经验,相较艾伯维、辉瑞的全球化体系及恒瑞药业的本土化网络,短板明显。

为弥补短板,凌科药业于2024年1月与先声药业达成战略合作:先声提供LNK01001强直性脊柱炎和类风湿关节炎适应症III期临床的CRO服务(含注册申报、临床管理),凌科药业按十个里程碑支付合计1.3653亿元服务费(已付9790万元),并约定2027年底前取得强直适应症上市批件,达标奖励最高750万元,逾期则赔付同等金额。

商业化方面,凌科药业负责生产供货,先声药业预付1.33亿元获得上述两大适应症国内独家销售权,负责推广并按市占率收取分级服务费等。

这一合作虽缓解了商业化压力,但凌科药业仍需面对产品上市后与先发产品的激烈竞争,其能否在差异化适应症或临床数据上形成突破,将决定后市表现。

总体来看,凌科药业的差异化管线描绘了美好蓝图,但在巨头先发优势、商业化短板与股权隐忧的多重夹击下,突围之路并非坦途。临床数据与执行效率能否兑现,才是决定其能否在蓝海中立足的真正胜负手。

注:文/孟祥娜,文章来源:创业最前线(公众号ID:chuangyezuiqianxian),本文为作者独立观点,不代表亿邦动力立场。

文章来源:创业最前线

广告
微信
朋友圈

FAQ回顾

凌科药业是做什么的?

凌科药业2017年由万昭奎等具备跨国药企研发背景的合伙人在杭州创立,专注自身免疫及炎症疾病小分子抑制剂研发,核心管线覆盖类风湿关节炎、强直性脊柱炎、特应性皮炎等适应症,当前正推进核心产品临床试验,二次递交招股书冲刺港交所上市。

国内自身免疫性疾病治疗药物市场规模有多大?

中国自身免疫性疾病治疗药物市场正高速扩容,规模从2019年的162亿元攀升至2024年的328亿元,机构预测2026年市场总量有望突破540亿元,目前以JAK抑制剂为代表的口服小分子靶向药物是赛道主流研发方向。

第二代JAK抑制剂有什么优势?

第二代高选择性JAK抑制剂可从源头抑制过度活化的免疫炎症,对自身免疫类疾病疗效明确,相比第一代泛JAK抑制剂能显著减少脱靶相关副作用,安全性更优,且口服给药相比注射生物制剂使用更便捷。

凌科药业如何弥补商业化短板?

凌科药业2024年1月与先声药业达成战略合作,先声药业提供核心管线LNK01001的临床CRO服务,还预付1.33亿元获得强直性脊柱炎、类风湿关节炎两大适应症国内独家销售权,负责后续市场推广,以此缓解商业化压力。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0